强生公司8月8日宣布,旗下创新治疗药物锐珂(埃万妥单抗注射液)正式获得国家药品监督管理局批准,联合利珂(甲磺酸兰泽替尼片)适用于携带表皮生长因子受体(EGFR)19号外显子缺失或21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。此次获批标志着埃万妥单抗在中国迎来了今年第三个肺癌适应症。此前,锐珂已获批用于携带EGFR 20号外显子插入突变的局部晚期或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.